文献速递肺栓塞与肺血管病肺结节与肺癌

利伐沙班与达肝素治疗癌症相关静脉血栓栓塞症的随机试验

Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
PubMed 文献 · Chest · 2021-10-08

该随机开放标签非劣效试验纳入158例活动性癌症合并近端深静脉血栓和/或肺栓塞患者,比较利伐沙班与达肝素治疗3个月的疗效与安全性。3个月时复发性VTE累积发生率利伐沙班组6.4%、达肝素组10.1%(SHR 0.75,95%CI 0.21-2.66),大出血分别为1.4%与3.7%(SHR 0.36,95%CI 0.04-3.43)。因样本量不足未达到预设非劣效标准,但疗效与安全性与既往DOAC研究一致。

要点

  • 利伐沙班治疗癌症相关VTE的复发率与大出血率数值上低于达肝素,但置信区间宽。
  • 研究样本量不足以达到预设非劣效标准,结果需结合既往DOAC证据解读。
  • 两组全因死亡率相近(25.7% vs 23.8%,HR 1.05,95%CI 0.56-1.97)。

核心结论

  • 在癌症相关VTE患者中,利伐沙班与达肝素的疗效和安全性结果与既往DOAC研究一致,但本试验样本量不足以达到预设非劣效标准。

研究设计与样本

  • 随机开放标签非劣效试验,纳入158例活动性癌症合并近端DVT和/或PE患者,随机接受利伐沙班(74例)或达肝素(84例)治疗3个月。
  • 患者平均年龄69.4岁,115例(76.2%)有转移性疾病。

主要发现

  • 主要结局(3个月复发性VTE累积发生率)利伐沙班组6.4%、达肝素组10.1%(SHR 0.75,95%CI 0.21-2.66)。
  • 大出血累积发生率利伐沙班组1.4%、达肝素组3.7%(SHR 0.36,95%CI 0.04-3.43)。
  • 大出血或临床相关非大出血累积发生率利伐沙班组12.2%、达肝素组9.8%(SHR 1.27,95%CI 0.49-3.26)。
  • 全因死亡利伐沙班组25.7%、达肝素组23.8%(HR 1.05,95%CI 0.56-1.97)。

临床怎么用

  • 利伐沙班可作为癌症相关VTE抗凝治疗的选项之一,但需结合患者出血风险个体化选择。
  • 治疗决策时应知晓本研究样本量有限、非劣效性未确立,可参考更新荟萃分析中DOAC与低分子肝素的整体证据。

局限性

  • 样本量不足,未达到预设的非劣效性标准。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated VTE. RESEARCH QUESTION: Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-associated VTE? STUDY DESIGN AND METHODS: In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months. The primary outcome was the cumulative incidence of recurrent VTE, a composite of symptomatic or incidental DVT or PE, and worsening of pulmonary vascular or venous obstruction at 3 months. RESULTS: Of 158 randomized patients, 74 and 84 patients were assigned to receive rivaroxaban and dalteparin, respectively. Mean age was 69.4 years, and 115 patients (76.2%) had metastatic disease. The primary outcome occurred in 4 and 6 patients in the rivaroxaban and dalteparin groups, respectively (both the intention-to-treat and per-protocol populations: cumulative incidence, 6.4% vs 10.1%; subdistribution hazard ratio [SHR], 0.75; 95% CI, 0.21-2.66). Major bleeding occurred in 1 and 3 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 1.4% vs 3.7%; SHR, 0.36; 95% CI, 0.04-3.43). Major or clinically relevant nonmajor bleeding occurred in 9 and 8 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 12.2% vs 9.8%; SHR, 1.27; 95% CI, 0.49-3.26). Overall, 19 patients (25.7%) and 20 patients (23.8%) died in the rivaroxaban and dalteparin groups, respectively (hazard ratio, 1.05; 95% CI, 0.56-1.97). INTERPRETATION: In this trial comparing rivaroxaban and dalteparin in the treatment of cancer-associated VTE, the number of patients was insufficient to reach the predefined criteria for noninferiority, but efficacy and safety results were consistent with those previously reported with DOACs. An updated meta-analysis of randomized trials comparing DOACs with low-molecular-weight heparin in patients with cancer-associated VTE is provided. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02746185; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. Chest. 2021. PMID: 34627853. doi:10.1016/j.chest.2021.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。